Navigation Links
Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
Date:6/28/2010

ORLANDO, Fla., June 28 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes.  The analysis showed that higher C-peptide levels had a statistically significant correlation with a decrease in two distinct measurements of glucose variability, confirming that C-peptide is a robust clinical marker for beta cell function which becomes impaired in type 1 diabetes.  Measurement of C-peptide has been endorsed by FDA as the primary endpoint for clinical trials of therapies that are designed to preserve beta cell function in new-onset type 1 diabetes and is the primary endpoint to evaluate the efficacy of otelixizumab in the DEFEND-1 clinical trial, with results from DEFEND-1 expected in the first half of 2011.  

The pre-dose baseline data from DEFEND-1 represents one of the first comprehensive studies to correlate higher C-peptide levels with lower blood glucose variability in patients with type 1 diabetes.  These results are clinically meaningful because blood glucose variability may be a risk factor for short- and long-term complications, including severe hypoglycemia and microvascular disease, in patients with type 1 diabetes.  The analysis from the DEFEND-1 study was presented at a poster session of the 70th Scientific Sessions of the American Diabetes Association (ADA) taking place June 25 through June 29 in Orlando, Florida. 

"We are gratified that the analysis of baseline data from our DEFEND-1 clinical trial may contribute to a better understanding of new-onset type 1 diabetes and
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
2. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
3. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
4. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
5. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
6. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
7. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
8. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
9. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
10. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
11. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
(Date:10/22/2014)... 2014   BioNano Genomics , the genome ... centers to purchase an Irys™ System . Among ... Institute (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope ... a comprehensive view of a genome was a ... not deliver the scalability or reliability to detect ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... and local dignitaries ushered in a new chapter in ... of a laboratory complex designed to speed up cures ... housing 78 labs and other facilities, signifies a break ... different fields and allowing them to communicate more effectively. ...
... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN ... a new study examining the immunogenicity and safety profiles of ... and younger adults to a standard dose of Fluzone vaccine. ... the Infectious Diseases Society of America on October 21, 2011. ...
Cached Medicine Technology:MUSC Dedicates New Bioengineering and Drug Discovery Hubs 2Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 2Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 3Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 4Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 5Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 6
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... Pass, OR (PRWEB) October 22, 2014 ... Southern California’s fresh water supply runs dangerously low, Southern ... change. Southern Oregon’s rivers, despite the lowest mountain snow ... even in late summer and early autumn.* That was ... authors of the new book “Hiking Southern Oregon,” during ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Although there are only ... time for many people who have trouble finding time within their ... to exercise for long periods of time to get in shape. ... goals while on the go. , Change Up Your Commute ... to work to add some exercise into your daily routine. If ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... 3.3 percent of children aged 2 to 19 are below ... number of underweight children aged 2 to 19 in the ... percent in 2003-2006, says a U.S. government study. , Being ... , Researchers at the U.S. Centers for Disease Control and ...
... , MEQUON, Wis., July 15 ... Maryland, has been recognized as the 2nd annual Wonderbox Technologies "Super ... Wonderbox Technologies staff during a special ceremony at the GDS offices ... Technologies performed an internal review of its clients, end users and ...
... BEIJING, July 15 New Enterprise Associates (NEA), ... four of its China-based portfolio companies were named to ... LianLian Pay, LineKong and Novast Pharmaceuticals. Spanning consumer technology, ... selected underscore the growth potential within several key areas ...
... on understanding of dilated cardiomyopathy , WEDNESDAY, July 15 ... disease and chronic heart failure in some children and ... , Dilated cardiomyopathy -- the most common cause of ... reason for a heart transplant -- is a condition ...
... memory of 10 minutes at this stage in development ... are only 30 weeks old may already possess short-term ... step into a better insight in the development of ... Jan G. Nijhuis, director of the Centre for Genetics, ...
... , , ... Inc., a leading provider of software and services for health and human ... management software company based in Killeen, Texas. Terms of the agreement were ... Crown provides Netsmart with a pharmacy management software solution, RxConnect, that will ...
Cached Medicine News:Health News:Wonderbox Technologies(R) Announces 2nd Annual Super User of the Year 2Health News:NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur 'Rising Stars' Honorees 2Health News:NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur 'Rising Stars' Honorees 3Health News:Gene Mutation Is Linked to Heart Muscle Disease 2Health News:Memory Forms at 30 Weeks in the Womb 2Health News:Memory Forms at 30 Weeks in the Womb 3Health News:Netsmart Technologies Acquires Pharmacy Management Software Company 2Health News:Netsmart Technologies Acquires Pharmacy Management Software Company 3
... Microvolume technology , The ADVIA 1650 has ... as 2 L/test), reagent consumption (as low ... L/hour) - thus maximizing management efficiency. , ... cycle and system throughput of up to ...
... and controls interchangeable with other Roche/Hitachi ... training costs. Consistent patient results throughout ... handling. 70 positions for routine, STAT ... volumes. Intermix sample types. Intermix 5 ...
With the sample processing core unit and intelligent process management, combines a wide variety of analytical modules to enable full consolidation of clinical chemistry and immunochemistry....
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
Medicine Products: